Min-ho Yoon

Busan, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Author Correction: Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome.

Author Correction: Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome.

Journal: Communications biology
Published: June 27, 2026

Author Correction: Human WRN is an intrinsic inhibitor of progerin, abnormal splicing product of lamin A.

Author Correction: Human WRN is an intrinsic inhibitor of progerin, abnormal splicing product of lamin A.

Journal: Scientific reports
Published: September 02, 2021

Novel chemical inhibitor against SOD1 misfolding and aggregation protects neuron-loss and ameliorates disease symptoms in ALS mouse model.

Novel chemical inhibitor against SOD1 misfolding and aggregation protects neuron-loss and ameliorates disease symptoms in ALS mouse model.

Journal: Communications biology
Published: June 07, 2021

RKIP Induction Promotes Tumor Differentiation via SOX2 Degradation in NF2-Deficient Conditions.

RKIP Induction Promotes Tumor Differentiation via SOX2 Degradation in NF2-Deficient Conditions.

Journal: Molecular cancer research : MCR
Published: May 19, 2021

Author Correction: Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome.

Author Correction: Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome.

Journal: Communications biology
Published: March 03, 2021

Human WRN is an intrinsic inhibitor of progerin, abnormal splicing product of lamin A.

Human WRN is an intrinsic inhibitor of progerin, abnormal splicing product of lamin A.

Journal: Scientific reports
Published: May 30, 2020

Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome.

Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome.

Journal: Communications biology
Published: February 12, 2020

p53 induces senescence through Lamin A/C stabilization-mediated nuclear deformation.

p53 induces senescence through Lamin A/C stabilization-mediated nuclear deformation.

Journal: Cell death & disease
Published: July 11, 2018

Laminopathies; Mutations on single gene and various human genetic diseases.

Laminopathies; Mutations on single gene and various human genetic diseases.

Journal: BMB reports
Published: April 25, 2018

Loss of NF2 Induces TGFβ Receptor 1-mediated Noncanonical and Oncogenic TGFβ Signaling: Implication of the Therapeutic Effect of TGFβ Receptor 1 Inhibitor on NF2 Syndrome.

Loss of NF2 Induces TGFβ Receptor 1-mediated Noncanonical and Oncogenic TGFβ Signaling: Implication of the Therapeutic Effect of TGFβ Receptor 1 Inhibitor on NF2 Syndrome.

Journal: Molecular cancer therapeutics
Published: December 11, 2017

Therapeutic Effect of Quinacrine, an Antiprotozoan Drug, by Selective Suppression of p-CHK1/2 in p53-Negative Malignant Cancers.

Therapeutic Effect of Quinacrine, an Antiprotozoan Drug, by Selective Suppression of p-CHK1/2 in p53-Negative Malignant Cancers.

Journal: Molecular cancer research : MCR
Published: September 14, 2017

Anti-cancer effect of novel PAK1 inhibitor via induction of PUMA-mediated cell death and p21-mediated cell cycle arrest.

Anti-cancer effect of novel PAK1 inhibitor via induction of PUMA-mediated cell death and p21-mediated cell cycle arrest.

Journal: Oncotarget
Published: June 20, 2016
Showing 1-12 of 19

Last Updated: 09/26/2026